Tamara Y Milder

7PUBLICATIONS
18CO-AUTHORS
Pharmaceutical delivery technologiesBehavioural epidemiologyBusiness analyticsAboriginal and Torres Strait Islander medicine and treatmentsFood properties (incl. characteristics and health benefits)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 28, 2026
Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025.

|Nov 08, 2024
Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?

Tamara Y Milder, Jialing Lin, Sallie-Anne Pearson

|Sep 03, 2024
Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018-2022.

Tamara Y Milder, Jialing Lin, Sallie-Anne Pearson

|Apr 15, 2024
Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.

Juliana de Oliveira Costa, Jialing Lin, Tamara Y Milder

|Oct 17, 2023
Sodium-Glucose Cotransporter 2 Inhibitor-Associated "Ketoacidosis" Versus "Diabetic Ketoacidosis": The Importance of Accurate Terminology.

Tamara Y Milder, David A Milder, Jerry R Greenfield

|Aug 07, 2023
'We are somehow fixated on this being a diabetes drug': a qualitative study exploring the views of cardiologists and nephrologists about sodium-glucose cotransporter 2 inhibitor initiation.

Tamara Y Milder, Sophie L Stocker, Melissa T Baysari

Pageof 2

Frequent Collaborators

5 joint publications

Jerry R Greenfield

4 joint publications

Sophie L Stocker

4 joint publications

Richard O Day

4 joint publications

Juliana de Oliveira Costa